Menu
Search
|

Menu

Close
X

AC Immune SA ACIU.OQ (NASDAQ Stock Exchange Global Market)

5.29 USD
-0.12 (-2.22%)
As of 12:41 PM EDT
Previous Close 5.41
Open 5.41
Volume 11,503
3m Avg Volume 30,796
Today’s High 5.43
Today’s Low 5.26
52 Week High 12.50
52 Week Low 3.25
Shares Outstanding (mil) 56.77
Market Capitalization (mil) 639.40
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, CHF)
FY19
77
FY18
7
FY17
20
FY16
23
EPS (CHF)
FY19
0.686
FY18
-0.822
FY17
-0.463
FY16
-0.167
*Note: Units in Millions of Swiss Francs
**Note: Units in Swiss Francs

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
113.23
7.91
Price to Book (MRQ)
vs sector
5.17
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
0.32
14.55
LT Debt to Equity (MRQ)
vs sector
0.32
10.20
Return on Investment (TTM)
vs sector
-32.55
14.48
Return on Equity (TTM)
vs sector
-33.72
15.78

EXECUTIVE LEADERSHIP

Douglas Williams
Chairman of the Board, Since 2019
Salary: --
Bonus: --
Andrea Pfeifer
Chief Executive Officer, Director, Since 2019
Salary: --
Bonus: --
Martin Velasco
Independent Vice Chairman of the Board, Since 2019
Salary: --
Bonus: --
Joerg Hornstein
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Jean-Fabien Monin
Chief Administrative Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

EPFL Innovation Park, Building B
LAUSANNE     1015

Phone: +4121.3459121

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

SPONSORED STORIES